Elicio Therapeutics is a Boston biotech developing lymph node targeted cancer immunotherapies, mainly for cancers with mutant KRAS. ELTX reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 24 | B. Riley Securities | Target lowered | Buy | |
| Aug 18 | HC Wainwright & Co. | Reiterated | Buy | |
| Jun 18 | Ladenburg Thalmann | Assumed coverage | Buy | |
| Jun 15 | HC Wainwright & Co. | Maintained | Buy | |
| Jun 10 | B. Riley Securities | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in ELTX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELTX is in one of them and how their past ELTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ELTX in an article yet. Here's the latest on the wider market.
About Elicio Therapeutics
Elicio Therapeutics is a biotechnology company based in Boston, Massachusetts, that is developing cancer immunotherapies. Its lead candidate, ELI-002 7P, is in clinical trials for pancreatic cancer and is also being studied in colorectal cancer. The company's treatments are designed to deliver immune signals to lymph nodes to generate T cell responses against tumors. Its target patients are those with cancers driven by mutant KRAS, a gene mutation found in many solid tumors.
- Headquarters
- Boston, MA